Cite
HARVARD Citation
Schmitz-Winnenthal, F. et al. (2018). A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology. p. . [Online].